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Abstract: Background: Despite undeniable evidence for the efficacy and effectiveness of Cognitive
Behaviour Therapy for Insomnia (CBT-I), the potential for its widespread dissemination and
implementation has yet to be realised. A suggested reason for this is that traditional CBT-I is
considered too burdensome for deployment, in its current form, within the context of where
it would be most beneficial—Primary Care. One strategy, aimed to address this, has been to
develop briefer versions of CBT-I, whilst another has been to deliver CBT-I in a group format.
An alternative has been to attempt to address insomnia during its acute phase with a view to
circumventing its progression to chronic insomnia. The aim of the present study was to compare
a brief version of CBT-I (one-shot) when delivered individually or in groups to those with acute
insomnia. Method: Twenty-eight individuals with acute insomnia (i.e., meeting full DSM-5 criteria for
insomnia disorder for less than three months) self-assigned to either a group or individual treatment
arm. Treatment consisted of a single one-hour session accompanied by a self-help pamphlet. Subjects
completed measures of insomnia severity, anxiety and depression pre-treatment and at one-month
post-treatment. Additionally, daily sleep diaries were compared between pre-treatment and at the
one-month follow up. Results: There were no significant between group differences in treatment
outcome on any sleep or mood measures although those in the group treatment arm were less
adherent than those who received individual treatment. Furthermore, the combined (group and
individual treatment arms) pre-post test effect size on insomnia symptoms, using the Insomnia
Severity Index, was large (d = 2.27). Discussion: It appears that group treatment is as efficacious
as individual treatment within the context of a “one shot” intervention for individuals with acute
insomnia. The results are discussed with a view to integrating one-shot CBT-I in Primary Care.
Keywords: acute insomnia; CBT-I; treatment; group therapy
1. Introduction
Insomnia is a significant public health concern affecting approximately 30%–36% of the population
in its subsyndromal form and between 8% and 15% in its syndromal, or chronic, form [1,2]. Not only
are the costs, both direct and indirect, associated with insomnia considerable but recent research points
to insomnia being a risk factor for the development and/or worsening of a myriad of other illnesses
and conditions [3–5]. Moreover, chronic insomnia appears to be persistent with studies demonstrating
both low natural remission rates [6] and high recurrence rates [7] over time. As such, there is a definite
need to address insomnia at both individual and societal levels.
Cognitive Behavioural Therapy for Insomnia (CBT-I), traditionally delivered individually
face-to-face over the course of 6–8 weeks, is now considered the first-line treatment option for
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individuals with chronic insomnia [8,9]. Through a series of taught techniques, the aim of CBT-I
is to increase the drive to sleep whilst eliminating any conditioned arousal to the bedroom and bedtime
routine, reducing sleep-related catastrophic worry and concerns and identifying and challenging
any pre-existing sleep-related dysfunctional attitudes and beliefs. In terms of its potency, there are
now a large number of meta-analyses (see Figure 1) which not only demonstrate the efficacy and
effectiveness of CBT-I, in the main, but also show that it can be successfully delivered in: (a) a group
context; (b) via digital technology; and (c) to individuals with a range of physical and psychological
co-morbidities [10]. That said, there are several issues that hamper the widespread dissemination
and implementation of CBT-I. Notably, and despite its relatively short duration compared to
other psychotherapeutic techniques, traditional CBT-I is often considered too burdensome in its
current format by patients [11,12] and this is reflected in the relatively high levels of attrition and
non-adherence, especially in clinical settings [13]. To that end, there have been several attempts
to modify traditional CBT-I into abbreviated versions [14–17] to address these issues of patient
burden. Whilst these studies have demonstrated good efficacy and effectiveness, the widespread
implementation and dissemination of CBT-I has yet to be realized [18].
 
Figure 1. An overview of CBT-I meta-analyses.  
Author Year Title
Morin et al. [19] 1994
Nonpharmacological interventions for insomnia: a meta-
analysis of treatment efficacy
Murtagh & Greenwood 12 [20] 1995
Identifying effective psychological treatments for 
insomnia: a meta-analysis
Pallesen et al. [21] 1998
Nonpharmacological interventions for insomnia in older 
adults: a meta-analysis of treat-ment efficacy
Montgomery & Dennis [22] 2003
Cognitive behavioral interventions for sleep problems in 
adults aged 60+
Irwin et al. [23] 2006
Comparative meta-analysis of behaviroral interventions 
for insomnia and their efficacy in middle-aged adults and 
in older adults 55+ years of age
Okajima et al. [24] 2011
A meta-analysis on the treatment effectiveness of 
cognitive behavioral therapy for primary insomnia
Mitchell et al. [25] 2012
Comparative effectiveness of cognitive behavioral 
therapy for insomnia: a systematic review
Miller et al. [26] 2014
The evidence base of sleep restriction therapy for treating 
insomnia disorder
Koffel et al. [27] 2015
A meta-analysis of group cognitive behavioral therapy 
for insomnia
Wu et al. [28] 2015
Cognitive behavioral therapy for insomnia comorbid 
with psychiatric and medical conditions
Trauer et al. [29] 2015 Cognitive behavioral therapy for chronic insomnia
Ho et al. [30] 2015
Self-help cognitive-behavioral therapy for insomnia: a 
meta-analysis of randomized controlled trials
Geiger-Brown et al. [31] 2015
Cognitive behavioral therapy in persons with comorbid 
insomnia: a meta-analysis
Tang et al. [32] 2015
Nonpharmacological treatments of insomnia for long-
term painful conditions: A systematic review and meta-
analysis of patient-reported outcomes in randomized 
controlled trials
Ye et al. [33] 2015
Internet-based cognitive behavioral therapy for insomnia 
(ICBT-i) improves comorbid anxiety and depression—a 
meta-analysis of randomized controlled trials
Zachariae et al. [34] 2016
Efficacy of internet-delivered cognitive-behavioral 
therapy for insomnia–A systematic review and meta-
analysis of randomized controlled trials
De Crescenzo et al. [35] 2016
Comparative efficacy and acceptability of 
pharmacological treatments for insomnia in adults: a 
systematic review and network meta-analysis
Johnson et al. [36] 2016
A systematic review and meta-analysis of randomized 
controlled trials of cognitive behavior therapy for 
insomnia (CBT-I) in cancer survivors
Seyffert et al. [37] 2016
Internet-Delivered Cognitive Behavioral Therapy to Treat 
Insomnia: A Systematic Review and Meta-Analysis
l .
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An alternative perspective, highlighted by Ellis and colleagues in 2012, is to circumvent the
development of chronic insomnia by attempting to treat it during its acute phase (i.e., within the first
three months of manifesting) [38]. The rationale for this being that treatment during the acute phase
should be even less burdensome for the patient and faster to administer due to: (i) less conditioned
arousal to the bedroom and pre-sleep routine; and (ii) a less realised self-schemata of having “insomnia”
which would be evidenced by lower levels of sleep-related catastrophic worry and sleep-related
dysfunctional thinking. Moreover, as the intimate link between insomnia and depression appears to
become realised during the acute phase of insomnia, Ellis and colleagues argue a need to treat acute
insomnia in its own right in an effort to aid in the prevention of depression [39]. To that end, Ellis,
Cushing and Germain [40] created a brief “one-shot” intervention for individuals with acute insomnia.
The one-shot consisted of a self-help pamphlet and a single 60–70 min face-to-face treatment session.
The pamphlet aimed to identify and address sleep-related dysfunctional thinking, through education
about sleep, provide techniques to distract from intrusive worrisome thoughts at night and provide the
guidelines for sleep-related stimulus control (using the bedroom for sleep and sex alone and leaving
the bedroom if unable to sleep). During the single treatment session a personalised sleep “restriction”
protocol is created which focuses on maximising sleep efficiency (the amount of time in bed spent
asleep) and increasing the depth and quality of sleep. They tested the efficacy and effectiveness of the
intervention in a Randomised Controlled Trial with 40 individuals with acute insomnia. One month
after delivery, 60% of those in the treatment arm had remitted whereas only 15% of those in the control
group had remitted. Further, the authors showed moderate effect sizes for reducing the time it took to
get off to sleep (d = 0.77), the amount of time awake during the night (d = 0.71) and a relative increase
in sleep efficiency (d = 0.69). Interestingly, three months following treatment, 73.3% of those in the
treatment arm had naturally remitted. Despite the success of this brief intervention there still remains
a need to determine whether it can be delivered even more efficiently, without losing its efficacy, when
considering the increasing financial and practical demands on healthcare services [41].
The aim of the present study was to examine the impact of group therapy versus individual
therapy for the single shot treatment in individuals with acute insomnia. In line with the meta-analytic
data from group delivered traditional CBT-I [27], it was expected that the one-shot within the context of
group therapy would be as impactful, both in terms of efficacy and effectiveness, than when delivered
on an individual basis.
2. Method
2.1. Participants
Subjects were recruited using two advertising posters, which were displayed for approximately
90 days each in community areas (e.g., libraries, and community centres) in two demographically
similar regions in the northeast United Kingdom. The posters were similar in design, asking for
individuals who had been suffering from acute insomnia to contact the research team with regard to
a new treatment study, except one poster stated the treatment session would be in groups whilst the
other stated that the treatment would be delivered individually. Each poster had a different contact
email address so the research team could track levels of interest for each treatment arm. In order
to be eligible participants had to be: (i) between the ages of 18 and 60 years old; (ii) within the first
three months of having insomnia; (iii) no history or current experience of CBT-I; and (iv) not currently
using sleep medication. Individuals who reported a suspected, untreated or unstable chronic illness or
a diagnosis, whether treated and stable, or not, of migraine, Post Traumatic Stress Disorder, epilepsy,
seizures, or Parasomnia were excluded from taking part. With respect to the diagnosis of acute
insomnia, in line with DSM-5 criteria for Insomnia Disorder, subjects had to report dissatisfaction with
their sleep characterised as either a difficulty getting off to sleep, staying asleep or waking earlier than
required. Further, the problem should exist despite adequate opportunity to sleep and should occur
for, at a minimum, three nights per week. Finally, subjects had to report that the insomnia results in
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significant impairment to daytime functioning or mood. Within the context of acute insomnia, subjects
had to report that the problem had been present for between two weeks and three months.
2.2. Procedure
Potential subjects that contacted the research team, from the email addresses on the poster, were
provided an information sheet, which outlined the commitment required by the subject (i.e., two visits
to the sleep research laboratory and the completion of questionnaires every week and sleep diaries
every day) in addition to the inclusion and exclusion criteria. Those who were eligible and still
wanted to take part were screened to ensure they met inclusion criteria and if still eligible were asked
to provide informed consent before being enrolled on to the respective arm of the study. Enrolled
subjects were sent a weeklong sleep diary and the questionnaires (Insomnia Severity Index [42],
Patient Health Questionnaire—9 [43], and General Anxiety Disorder—7 [44]), for baseline assessment,
and were provided an appointment date and time, at the sleep research laboratory, to attend the
treatment session approximately a week following enrolment. Subjects were instructed to bring the
completed questionnaires and sleep diary with them to the session. The procedure for the “one-shot”
insomnia treatment is published elsewhere [40]. However, the group therapy subjects were treated
in groups of 4. Two Master’s level psychologists delivered treatment and both were trained and
supervised by an experienced CBT-I therapist (JGE). During the treatment session subjects’ baseline
sleep diaries were used to create personalised sleep plans to follow for the duration of the study.
From the personalised sleep plan the average amount of sleep obtained per night (mean Total Sleep
Time (TST)) was derived from the baseline sleep diary. TST was then set at the amount of time the
individual was required to be in bed each night over the following week (Prescribed Time In Bed
(PTIB)) as long as the average was a minimum five hours in duration. If the average from the sleep
diaries was less than five hours then PTIB was set at five hours. The subjects, following instruction,
and then checked by the investigators during the treatment session, calculated their PTIB. From this
point subjects “anchored” their Prescribed Time Out of Bed (PTOB), usually to the time they had to
be up in the morning owing to work or social commitments, and then subjects worked backwards
to derive their Prescribed Time To Bed (PTTB) for the week. Subjects were told to stick with their
personalised sleep plan even on non-work days. At the session subjects were also told that following
a week of this new plan they were to titrate their prescription based upon their Sleep Efficiency
averages from the week using the following rules: less than 85% SE they were to increase their PTTB
by 15 min (i.e., from 12:45 a.m. to 1:00 a.m.), a SE between 85% and 90% to stay with their current
schedule and a SE of more than 90% they were to reduce their PTTB by 15 min (i.e., from 12:45 a.m.
to 12:30 a.m.). Again, subjects were told not to go below the minimum threshold of five hours PTIB.
Finally, subjects were told to titrate at the end of each week for the remaining duration of the study.
On completion of the treatment session subjects were provided four weeklong sleep diaries to complete
over the duration of the study and a follow-up appointment was made for them to return the diaries
and complete the same questionnaires that they completed at baseline. On completion of the study,
subjects were thanked, debriefed and offered additional support (i.e., a full six week course of CBT-I) if
necessary. The study had been granted ethical approval by Northumbria University Ethics Committee
(SUB33_300315 & SUB17_180315).
2.3. Measures
The Insomnia Severity Index (ISI) is a 7-item self-report indicator of the presence and severity
of insomnia. It takes approximately 5 min to complete. The scale has been used extensively and has
excellent psychometric properties [42]. Furthermore, the ISI has been shown to be sensitive to change
following intervention [45]. For the purposes of the present study, subjects were asked to complete the
ISI on the basis of the last week. Scores range between 0 and 28 with higher scores indicating higher
insomnia symptomology.
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The Patient Health Questionnaire (PHQ 9) is a 9-item self-report questionnaire that examines
depression severity. It takes approximately 5 min to complete. The scale is suitable for assessing
depression and monitoring change following intervention and has been used extensively in
health-related research. It has excellent psychometric properties and is sensitive to change following
intervention. For the purpose of the present study the reporting period was matched to that of the
other questionnaires and subjects reported on the basis of the last week. For the purposes of analysis,
item 3 “Trouble falling or staying asleep, or sleeping too much” was excluded. As such scores ranged
from 0 to 24 with higher scores indicating higher depression symptomology.
The GAD-7 is a 7-item self-report questionnaire that examines anxiety severity. It takes
approximately 3 min to complete. The scale is suitable for assessing Generalized Anxiety Disorder
and monitoring change following intervention and has been used extensively in primary care research.
Scores on the GAD-7 range between 0 and 21 with higher scores indicating higher anxiety symptomology.
It has excellent psychometric properties and is sensitive to change following intervention. As with the
ISI and PHQ-9, subjects were asked to report on the basis of the previous week.
The Consensus Sleep Diary [46] contains 10 items relating to the previous night’s sleep. Subjects
were asked to complete the sleep diary each morning over the duration of the study, approximately
20–40 min after awakening. From the sleep diary the variables of interest related to the main symptoms
of insomnia and were derived from the data averaged over the previous week—Sleep Latency (the time
elapsed between intending to sleep and sleeping), Wake After Sleep Onset (the duration of time awake
over the course of the night not including sleep latency), Sleep Efficiency (the amount of time spent in
bed asleep over the duration of time spend in bed overall—expressed as a percentage) and Total Sleep
Time (the amount of sleep obtained).
2.4. Analytic Strategy
Baseline differences in demographic characteristics and self-reported sleep were examined using
a series of t-tests. Following checks for normality and homogeneity, a mixed ANOVA was used to
examine between and within group differences on the primary outcome measure (i.e., ISI scores).
Further, pre-post treatment change scores were used in a multivariate ANOVA to examine group
differences and to calculate effect sizes. As in the earlier trial of a “one shot” CBT-I treatment for
individuals with acute insomnia [40], adherence was operationalized and calculated as an average
number of minutes, from the first weeklong sleep diary following treatment, that the subject
was outside their Prescribed Time in Bed and if this average was outside 15 min subjects were
considered non-adherent.
3. Results
There were 13 enquiries to the group treatment arm, by eligible subjects, whereas there were
15 to the individual treatment arm. However, one subject in the group treatment arm and two in
the individual treatment arm did not complete the study. Of note, despite the posters advertising
for individuals with acute insomnia there were a number of enquiries by individuals with chronic
insomnia to both studies (n = 11 in the individual arm and n = 8 in the group arm). The final sample
consisted of 19 females and six males. In the group treatment arm, there were 10 females and three
males and in the individual treatment arm there were 9 females and 3 males. There were no differences
between the groups in terms of age (group arm, Mean Age 39.62 ± 13.64; individual arm, Mean Age
42.00± 17.83) or sex (both at p > 0.05). There were no significant between group differences, at baseline,
on any of the reported measures (all at p > 0.05) (see Table 1).
A mixed ANOVA was used to examine group by time changes on scores on the primary outcome
measure (i.e., Insomnia Severity Index Scores). There was no interaction effect (Wilks Lambda = 0.94,
F(1,23) = 1.4, p > 0.05, partial eta squared = 0.06) or a main effect for group (F(1,23) = 0.03, p > 0.05, partial
eta squared = 0.001) but there was a main effect for time (Wilks Lambda = 0.2, F(1,23) = 93.14, p < 0.001,
partial eta squared = 0.8). Following a one-way multivariate analysis of variance on pre-post change
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scores for each of the variables of interest, psychometric scales (PHQ-9, GAD-7, ISI) and sleep diaries
(TST, SL, WASO, SE) revealed the overall model was not significant (F(7,17) = 0.6, p > 0.05—Pillai’s
Trace = 0.2, partial eta squared = 0.2). Further analysis of each scale and sleep diary item revealed no
between-group differences on any dimension (all at p > 0.05).
Table 1. Means and Standard Deviations by Group.
Variables
Baseline Follow-Up
Change Scores
Group (n = 13) Individual (n = 12) Group (n = 13) Individual (n = 12)
PHQ-9 7.39 (5.46) 6.92 (2.68) 2.15 (2.58) 3.5 (1.68) −4.36 (3.92)
GAD-7 7.08 (5.14) 8.00 (3.44) 2.54 (2.6) 3.75 (1.91) −4.4 (4.26)
ISI 15.92 (6.14) 14.5 (3.8) 5.15 (3.69) 6.08 (2.61) −9.64 (5.01)
SL 27.95 (25.58) 28.53 (17.81) 10.8 (6.93) 12.24 (7.57) −16.73 (19.81)
WASO 54.33 (35.63) 28.65 (26.98) 17.1 (13.92) 14.62 (14.89) −26.11 (33.58)
SE 74.75 (13.54) 78.83 (9.81) 89.19 (4.83) 87.46 (7.58) 11.65 (13.21)
TST 397.55 (76.9) 425 (35.71) 407.47 (53.68) 433.45 (41.91) 9.21 (52.01)
PHQ-9: Patient Health Questionnaire; GAD-7: Generalized Anxiety Disorder; ISI: Insomnia Severity Index;
SL: Sleep Latency; WASO: Wake After Sleep Onset; SE: Sleep Efficiency; TST:Total Sleep Time.
In terms of a responder analysis, using the criteria of a score of ≤8 on the ISI, nine out of the
13 participants (69.23%) no longer met criteria for insomnia in the group treatment condition and nine
out of 12 (75%) participants in the individual treatment group no longer met criteria for insomnia at
the one-month follow-up. There were no significant between-group differences in effectiveness using
this criterion (Fishers Exact X2 (1) = 0.1, p > 0.05). With regard to symptom reduction, in line with
Morin and colleagues [36] (i.e., a reduction of 7 points on the ISI), nine out of 13 (69.23%) subjects in
the group arm showed an improvement, whereas 10 out of 12 (83.33%) subjects in the individual arm
showed an improvement. There was no difference in treatment response between groups (Fishers
Exact X2 (1) = 0.68, p > 0.05).
Considering there were no apparent differences between the groups, Cohen’s d effect sizes were
calculated, from pre-post means and standard deviations, for each variable of interest from the overall
sample. The results show high effect sizes for PHQ-9 (d = 1.28), GAD-7 (d = 1.26), ISI (d = 2.27), Sleep
Latency (d = 1.06), Wake after Sleep Onset (d = 1.01) and Sleep Efficiency (d = 1.23). As expected,
the Cohen’s d for Total Sleep Time (d = 0.17) was small.
Finally, using the criteria of adherence (i.e., those, on average, who were within 15 min of their
PTIB), 7 (53.85%) of the subjects in the group treatment arm were adherent versus 11 (91.67%) in the
individual treatment arm. A chi-square demonstrated a significant difference between the groups
(Fishers Exact X2 (1) = 4.43, p < 0.05) with those in the individual treatment arm demonstrating higher
adherence levels than those in the group treatment arm.
4. Discussion
The present study sought to examine whether the “one shot” CBT-I could be used in a group
treatment format and provide an, albeit preliminary, examination of the comparative efficacy and
effectiveness of group therapy compared to individual therapy within the context of acute insomnia.
In line with the hypothesis, the results suggest that in terms of the symptoms and treatment
outcomes with respect to sleep and insomnia, with the exception of adherence, group treatment appears
to be comparable to individual treatment. Whilst this finding is certainly not new within the context of
chronic insomnia and the standard duration of CBT-I [27,47], this is interesting within the confines of
acute insomnia and the “one-shot” treatment strategy. These findings suggest that it is plausible to
deliver this intervention to individuals with acute insomnia in a very intensive manner (i.e., via groups)
without reducing its efficacy or effectiveness. This naturally will aid in its potential for widespread
dissemination and implementation in settings where it may be needed most (i.e., Primary Care), as
it will be attractive to both patients and the agencies responsible for healthcare delivery. That said,
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there is concern with regard to levels of adherence in the group treatment arm, with just under half
of the subjects meeting the criteria for being non-adherent. Interestingly, however, it would appear
that levels of adherence have not impacted heavily on treatment outcome, although again sample
size should be noted here. One possible explanation for this disparity in findings (non-adherence not
influencing treatment outcome) is considering at present that there is no “gold standard” definition of
adherence following CBT-I it may be that the criteria set down in the present study may have been
too conservative and that variations outside this threshold of prescribed time in and out of bed do
not impact on treatment outcome. Alternatively, it could be conceivable that the “sleep restriction”
prescription, on which adherence rates were based in this study, may not be integral to treatment
outcome in this population and a different measure of adherence is needed within the context of
acute insomnia. Irrespective, adherence will need to be examined more closely in a larger trial, ideally
a randomised control trial, of the intervention and if necessary the “one-shot” may need to be adapted
to address adherence before widespread deployment.
Interestingly, the results suggest that, irrespective of delivery format (group or individual),
the “one-shot” appears not only to confer a positive impact on insomnia severity and self-reported
symptoms of insomnia (sleep latency and wake after sleep onset), but also impacts of the symptoms
of anxiety and depression. Whilst this has been previously demonstrated in samples with chronic
insomnia, using a “traditional” CBT-I approach [48,49], this is the first time these results have been
shown within the context of a brief version of CBT-I or for those with acute insomnia. That said, these
results should be viewed with a certain degree of caution as it is unknown whether this reduction
in symptoms was due to the intervention or whether a level of natural remission occurs, in terms of
the symptoms of anxiety and depression, over the early developmental course of insomnia. Sadly,
the small sample size precluded a fine-grained analysis of this question.
The results should be viewed within the context of a few limitations. Primarily this was
a relatively small self-selecting sample. More specifically, uptake was very low considering the
suggested prevalence and incidence of acute insomnia in the general population [2]. Whether this
speaks to the context of recruitment within community settings used in the present study or more
broadly to a need to increase health literacy with regard to insomnia in general and acute insomnia
specifically, so that appropriate pathways to prevention and treatment can be created, is unknown.
Certainly it would be interesting to compare differences in uptake if the same study were to be
advertised within the context of Primary Care as opposed to in community settings. Further, it should
also be acknowledged that the groups were relatively small (i.e., four people) and so it is unknown
whether the present findings would be translatable to bigger groups. That said, to date there is limited
evidence on optimal group size within the context of the treatment of insomnia and as such it would
be difficult to make any conclusions as to whether the small group size had a positive, or indeed
negative, influence on treatment outcomes. Additionally, as subjects were not randomly allocated to
either individual or group therapy we are unable to make any inferences about the acceptability of
the different interventions. Certainly, the next step in this research agenda is to conduct a full RCT,
which will include a no-treatment control group, additionally focusing on the acceptability of the
different treatment modalities, for people with acute insomnia. Finally, the measure of adherence
in the current study could be considered a limitation. Defining adherence on the basis of the first
week of sleep diaries following treatment, although used previously [40], only provides data on initial
adherence to the sleep restriction aspect of the overall CBT-I and nothing more.
5. Conclusions
In summary, the present study demonstrates, albeit rather preliminarily, that a “one-shot”
intervention for acute insomnia could be delivered in a group context without losing efficacy or
effectiveness, at least compared to it being delivered individually. Moreover, the intervention,
irrespective of its delivery modality, appears to confer benefits “above and beyond” sleep itself with
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an impact on the symptoms of depression and anxiety. However, issues of uptake and adherence will
need to be addressed before wide scale dissemination and implementation can occur in Primary Care.
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